The neuroendocrine tumor program at Rush offers the most advanced care in Illinois. Rush is the first hospital in the state to use 68-Gallium DOTATATE PET CT, the most sensitive diagnostic test for neuroendocrine tumors. It’s also the first to offer peptide receptor radionuclide therapy (PRRT), which is designed to safely kill neuroendocrine cancer cells that have spread to multiple places in the body.
Just as important, Rush has a team of caring physicians who specialize in treating all types of neuroendocrine tumors:
- Neuroendocrine tumors of the gastrointestinal tract and lungs (including carcinoid tumors)
- Neuroendocrine tumors of the pancreas (including insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma and nonfunctioning)
- Neuroendocrine tumors of the pituitary gland
- Neuroendocrine tumors resulting from genetic conditions such as Von Hippel-Lindau syndrome, multiple endocrine neoplasia Type 1, neurofibromatosis and tuberous sclerosis
- Medullary thyroid cancer
- Pheochromocytomas and paragangliomas
Care tailored to you
These tumors occur in different places because the neuroendocrine cells in which they develop are found throughout your body. And depending on their location and type, they may be slow-growing or aggressive.
Since neuroendocrine tumors are so varied, there are several possible treatments — including some that became available only recently. It takes physicians with experience and specialized knowledge to determine which option will work best for you. That’s where the team at Rush comes in.
As a patient in the neuroendocrine tumor program, you’ll have access to every specialist you might need, including surgeons, gastroenterologists, diagnostic and interventional radiologists, nuclear medicine specialists, medical oncologists, pathologists, geneticists and endocrinologists.
Your care team will work with you to develop a comprehensive treatment plan that is based on the most up-to-date research and tailored to your needs. Physicians at Rush are also researchers investigating new treatments, and through clinical trials they can offer options that are not otherwise available.